This trial is testing the side effects and effectiveness of combining four drugs to treat patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
2 Primary · 5 Secondary · Reporting Duration: Up to 12 months
Experimental Treatment
80 Total Participants · 1 Treatment Group
Primary Treatment: Quizartinib · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: